These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
Nevada
|
20-2781289
|
|
(State
or other jurisdiction of
|
(I.R.S.
Employer
|
|
incorporation
or organization)
|
Identification
No.)
|
|
Bath
House
|
|
|
8
Chapel Place
|
|
|
London,
United Kingdom
|
EC2A
3DQ
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Large
accelerated filer
¨
|
Accelerated
filer
¨
|
|
Non-accelerated
filer
¨
(Do
not check if a smaller reporting company)
|
Smaller
reporting company
x
|
|
•
|
our
ability to raise capital to finance our growth and operations, when needed
and terms advantageous to us;
|
|
•
|
the
ability to manage growth, profitability and the marketability of our
products and services;
|
|
•
|
general
economic and business conditions;
|
|
•
|
the
effect on our business of recent credit-tightening throughout the
world;
|
|
•
|
the
impact of developments and competition within the fossil fuels and
alternative energy industries;
|
|
•
|
adverse
results of any legal proceedings;
|
|
•
|
the
impact of current, pending or future legislation and regulation on the
fossil fuels and alternative energy industries, including, but not limited
to, changes in zoning and environmental laws and
regulations;
|
|
•
|
our
ability to maintain and enter into relationships with suppliers, vendors
or contractors of acceptable quality of goods and services on terms
advantageous to us;
|
|
•
|
changes
in foreign currency exchange rates;
|
|
•
|
political
and government changes in the countries (including local and regional
governments) in which we operate;
|
|
•
|
the
volatility of our operating results and financial
condition;
|
|
•
|
our
ability to attract and retain qualified senior management personnel;
and
|
|
•
|
the
other risks and uncertainties detailed in this Form 10-K and, from time to
time, in our other filings with the Securities and Exchange
Commission.
|
|
Item
1.
|
Business.
|
|
•
|
produce
high-density, short-rotation biomass crops on a commercial scale at a cost
of production competitive with the price of coal (measure in energy terms
– MMBtu) using a proprietary integrated farming model,
and
|
|
•
|
to
produce power, steam, hydrogen, transport fuel, fertilizers, pesticides,
chemicals and other important products through advanced gasification and
steam technologies.
|
|
•
|
We
have entered into a Memorandum of Agreement with Growmore Biotech of
Bangalore Limited (“GBB”) for GBB to supply 100,000 trees per week of
micro-propagated Beema Bamboo, Paulownia and Vanashree trees. Growmore
Biotech were vested 1 million Clenergen Corporation shares (valued at
$1.00 per share), in return for a discount of 30% to market value. Each
sapling will be uniform, disease resistant, and asexual, therefore a non
invasive species and fire
retardant.
|
|
•
|
We
have entered into an engagement letter with a leading Indian merchant bank
for a possible public offering of minority interests in and debt
securities of Clenergen India. We intend to utilize the net proceeds of
such equity and debt offerings to purchase equipment, retain plantation
management, finance the upgrade of the capacity of the Salem, Tamilnadu
anaerobic digestion power plant, acquire the Chennai combustion steam
power plant, construct the Tirunelevi, Tamilnadu combustion steam or
gasification technology based power plant and pay the set up costs of
plantations on the land under
lease.
|
|
Company Name
|
Place of
Incorporation
|
Percentage
Ownership
|
Direct Parent Corporation
|
||||||
|
Clenergen Corporation
Limited (UK)
|
United
Kingdom
|
100%
|
Clenergen
Corporation
|
||||||
|
Clenergen
India Private Limited
|
India
|
99.99%
|
Clenergen
Corporation Limited (UK)
|
||||||
|
Clenergen
Biopower Corporation
|
Florida,
USA
|
19%
(1)
|
Clenergen
Corporation
|
|
(1)
|
Mark
Quinn, our President and Chief Executive Officer, and Jessica Hatfield,
our Executive Vice President, each own 16% of Clenergen Biopower
Corporation.
|
|
Item
1A.
|
Risk
Factors.
|
|
Item
2.
|
Properties.
|
|
Item
3.
|
Legal
Proceedings.
|
|
Item 4.
|
Submission
of Matters to a Vote of Security
Holders.
|
|
Item 5.
|
Market
for Common Equity and Related Stockholder
Matters.
|
|
•
|
contains
a description of the nature and level of risk in the market for penny
stocks in both public offerings and secondary
trading;
|
|
•
|
contains
a description of the broker’s or dealer’s duties to the customer and of
the rights and remedies available to the customer with respect to a
violation to such duties or other requirements of the Securities Act of
1934, as amended;
|
|
•
|
contains
a brief, clear, narrative description of a dealer market, including “bid”
and “ask” prices for penny stocks and the significance of the spread
between the bid and ask price;
|
|
•
|
contains
a toll-free telephone number for inquiries on disciplinary
actions;
|
|
•
|
defines
significant terms in the disclosure document or in the conduct of trading
penny stocks; and
|
|
•
|
contains
such other information and is in such form (including language, type, size
and format) as the SEC shall require by rule or
regulation.
|
|
•
|
the
bid and offer quotations for the penny
stock;
|
|
•
|
the
compensation of the broker-dealer and its salesperson in the
transaction;
|
|
•
|
the
number of shares to which such bid and ask prices apply, or other
comparable information relating to the depth and liquidity of the market
for such stock; and
|
|
•
|
monthly
account statements showing the market value of each penny stock held in
the customer’s account.
|
|
Quarter
Ended
|
High
|
Low
|
||||||
|
October
31, 2009
|
$ | 1.40 | $ | 0.71 | ||||
|
July
31, 2009
|
n/a | n/a | ||||||
|
April
30, 2009
|
n/a | n/a | ||||||
|
January
31, 2009
|
n/a | n/a | ||||||
|
October
31, 2008
|
n/a | n/a | ||||||
|
July
31, 2008
|
n/a | n/a | ||||||
|
April
30, 2008
|
n/a | n/a | ||||||
|
January
31, 2008
|
n/a | n/a | ||||||
|
Item
6.
|
Selected
Financial Data.
|
|
Item
7.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations.
|
|
General,
administrative and corporate expenses
|
$ | 600,000 | ||
|
Professional
fees
|
920,000 | |||
| Lease of 5,000 acre plantation in Guyana and commencement of field trials | 200,000 | |||
|
Acquisition
of Chennai 18 MWe biomass power plant
|
7,000,000 | |||
|
Deposits
on purchases of land for plantations in India; start up costs for Salem
1.5 MWe power plant; repayment of short term loans (India); and
finalization and deposit for construction of Tirunelveli 32 MWe biomass
power plant
|
2,500,000 | |||
|
Licensing
fee for polyploidy technology
|
200,000 | |||
|
Feasibility
study for National Power Corporation (Philippines)
|
250,000 | |||
|
Capital
equipment for the upgrade to 10MWe at the Salem 1.5MWe power plant
and Construction of the 32MWe power plant in
Tirunelveli
|
48,393,965 | |||
|
Total
|
$ | 60,063,965 |
|
Year Ended October 31,
|
Period from
October 27,
2005
(Inception) to
October 31,
|
|||||||||||
|
2009
|
2008
|
2009
|
||||||||||
|
Revenue
|
$ | 0 | $ | 0 | $ | 0 | ||||||
|
Operating
expenses
|
1,072,695 | 972 | 4,963,818 | |||||||||
|
Net
loss from operations
|
(1,072,695 | ) | (972 | ) | (4,963,818 | ) | ||||||
|
|
Period from
|
|||||||||||
|
|
October 27,
2005
|
|||||||||||
|
|
Year Ended
|
(Inception) to
|
||||||||||
|
|
October 31
|
October 31,
|
||||||||||
|
|
2009
|
2008
|
2009
|
|||||||||
|
Research
and development
|
$ | 0 | $ | 175 | $ | 2,275,043 | ||||||
|
General
and administrative
|
$ | 1,072,695 | $ | 797 | $ | 2,688,775 | ||||||
|
Year Ended
October 31,
2009
|
Year Ended
October 31,
2008
|
Increase /
(Decrease)
|
||||||||||
|
Net
Cash Used in Operating Activities
|
$ | (899,125 | ) | $ | (33,132 | ) | $ | 865,993 | ||||
|
Net
Cash Used in Investing Activities
|
$ | (14,041 | ) |
$
|
Nil | $ | 14,041 | |||||
|
Net
Cash (Used In) Provided by Financing Activities
|
$ | 941,550 | $ | (861,187 | ) | $ | (1,802,737 | ) | ||||
|
Effect
of Exchange Rate on Cash
|
$ | (26,924 | ) | $ | 416,880 | $ | 389,956 | |||||
|
Net
Increase in Cash
|
$ | 1,460 | $ | (18 | ) | $ | 1,442 | |||||
|
Item
8.
|
Financial
Statements.
|
|
Item
|
Page
*
|
|
|
Report
of Independent Registered Public Accounting Firm
|
F-1
|
|
|
Consolidated
Balance Sheets at October 31, 2009 and 2008
|
F-2
|
|
|
Consolidated
Statements of Operations for the Years Ended October 31, 2009 and 2008 and
from October 27, 2005 (inception) to October 31, 2009
|
F-4
|
|
|
Consolidated
Statement of Changes in Stockholders’ Deficiency for the Years Ended
October 31, 2009 and 2008 and from October 27, 2005 (inception) to October
31, 2009
|
F-5
|
|
|
Consolidated
Statements of Cash Flows for the Years Ended October 31, 2009 and 2008 and
from October 27, 2005 (inception) to October 31, 2009
|
F-6
|
|
|
Notes
to Consolidated Financial Statements
|
F-7
|
|
*
|
Page
F-1 follows page 45 to this Annual Report on Form
10-K.
|
|
Item 9.
|
Changes
In and Disagreements with Accountants on Financial
Disclosure.
|
|
|
Controls
and Procedures.
|
|
•
|
lack
of a functioning audit committee due to a lack of a majority of
independent members and a lack of a majority of outside directors on our
board of directors, resulting in ineffective oversight in the
establishment and monitoring of required internal controls and
procedures;
|
|
•
|
inadequate
segregation of duties consistent with control objectives;
and
|
|
•
|
ineffective
controls over period end financial disclosure and reporting
processes.
|
|
•
|
transactions
are recorded as necessary to permit preparation of financial statements in
accordance with accounting principles generally accepted in the United
States;
|
|
•
|
receipts
and expenditures are being made only in accordance with authorizations of
management and the directors of our Company;
and
|
|
•
|
unauthorized
acquisition, use or disposition of our assets that could have a material
effect on our financial statements are prevented or timely
detected.
|
|
Item 9B.
|
Other
Information.
|
|
Item 10.
|
Directors
and Executive Officers.
|
|
Name
|
Position Held
with the Company
|
Age
|
Date First Elected
or Appointed
|
|||
|
Mark
Quinn
|
Chief
Executive Officer and Director
|
49
|
March
16, 2009
|
|||
|
Jessica
Hatfield
|
Executive
Vice President and Director
|
51
|
March
16, 2009
|
|||
|
Dr.
Arvind Pandalai
|
Non
Executive Group Chairman
of
the Board of Directors
|
60
|
November
5, 2009
|
|||
|
Robert
Kohn
|
Non
Executive Vice Chairman
of
the Board of Directors
|
63
|
November
5, 2009
|
|||
|
David
Sonnenberg
|
Director
|
58
|
November
5, 2009
|
|||
|
Mike
Starkie
|
|
President
and Acting Chief Financial Officer
|
|
63
|
|
February
5, 2010
|
|
Item
11.
|
Executive
Compensation.
|
|
Annual Compensation
|
Long-Term
Compensation Awards
|
|||||||||||||||
|
Name and Principal
Position
|
Fiscal Year Ended
October 31,
|
Salary
|
Bonus
|
Other Annual
Compensation
|
Securities Underlying
Options
|
|||||||||||
|
Mark
Quinn, CFO and
|
2009
|
$ | 0 | $ | 0 | $ | 0 | (2)(5) |
None
|
|||||||
|
President
(1)
|
2008
|
$ | 0 | $ | 0 | 0 | (2) |
None
|
||||||||
|
Jessica
Hatfield,
|
2009
|
$ | 0 | $ | 0 | $ | 0 | (2)(6) |
None
|
|||||||
|
Executive
Vice-President (4)
|
2008
|
$ | 0 | $ | 0 | $ | 0 | (2) |
None
|
|||||||
|
Wolf
Seyfert,
|
2009
|
$ | 0 | $ | 0 | $ | 0 | (2) |
None
|
|||||||
|
Former
CFO and
|
2008
|
$ | 0 | $ | 0 | $ | 0 | (2) |
None
|
|||||||
|
Former
President (6)
|
||||||||||||||||
|
(1)
|
Mr.
Quinn was appointed as our President, Chief Executive Officer, Chief
Financial Officer and director on March 16, 2009. Mr. Quinn
resigned as our President and Chief Financial Officer on August 30,
2009.
|
|
(2)
|
Does
not include perquisites which totaled under $10,000 for each of the 2009
Fiscal Year and 2008 Fiscal Year.
|
|
(3)
|
Ms.
Hatfield was appointed as our Executive Vice-President and director on
March 16
th
,
2009.
|
|
(4)
|
Mr.
Seyfert resigned as our President, Chief Executive Officer, Chief
Financial Officer and Director on March 16,
2009.
|
|
(5)
|
Does
not include the 760 shares of common stock Mr. Quinn held in
Clenergen Corporation Limited which were exchanged for Clenergen
Corporation shares under the terms of the share exchange agreement signed
in August 2009.
|
|
(6)
|
Does
not include the 760 shares of common stock Ms
Hatfield held in Clenergen Corporation Limited which were
exchanged for Clenergen Corporation shares under the terms of the share
exchange agreement signed in August
2009.
|
|
|
·
|
Assuming
the role of Group Chairman of Clenergen
Corporation
|
|
|
·
|
Engaging in
press conferences and interviews with both the press and other media
channels.
|
|
|
·
|
Chairing
all Board of Directors meetings and retain the casting vote where
applicable.
|
|
|
·
|
Ensuring the
company meets all compliance regulations both with the US and Indian
regulatory authorities.
|
|
|
·
|
Appointing
the Chief Executive officer and Chief Financial officer of Clenergen India
Private Limited who will report to the Chairman
directly.
|
|
|
·
|
Appointing
an accredited accounting firm to perform detailed audits on behalf of
Clenergen India Private Limited.
|
|
|
·
|
Assuming
the position and responsibilities of a Director of Clenergen
Corporation.
|
|
|
·
|
Attending
meetings of the Board of Directors to be held on a quarterly
basis
|
|
|
·
|
Managing
and operate the Clenergen Foundation and oversee projects designated in
the regions where the company maintains
operations.
|
|
|
·
|
Appointing
a public relations company and manage all communications between Clenergen
Corporation and the PR company.
|
|
|
·
|
Proof
read and approve all press releases and ensure maximum circulation upon
release.
|
|
|
·
|
Managing
and attend conferences as designated by the Board of Directors and
preparation of all display and marketing materials as
required.
|
|
|
·
|
Promoting
the services of the company to mining companies and large end users
located in Central and Southern America, Africa and
India.
|
|
|
·
|
Acting
as Non Executive Vice Chairman of Clenergen Corporation, and developing a
management team for the business development activities in USA and
Canada
|
|
|
·
|
Overseeing
all filings and corporate governance and compliance with OTC and SEC
regulation
|
|
|
·
|
Securing
equity investment on behalf of Clenergen
Corporation
|
|
|
·
|
Negotiatating
and entering into strategic alliance and joint venture agreements with
companies based in the USA, Canada and South
America.
|
|
|
·
|
Securing
private placement of shares with reputable third
parties
|
|
|
·
|
Performing
the duties of Chief Executive Officer of Clenergen
Corporation
|
|
|
·
|
Attending
meetings of the Board of Directors to be held on a quarterly
basis
|
|
|
·
|
overseeing
the hiring and training of Senior Management of the
Company.
|
|
|
·
|
establishing
wholly owned subsidiary companies in various regions where the company
will be operational
|
|
|
·
|
interactacting
with the stock markets and attend press conferences on behalf of the
company.
|
|
|
·
|
Ensuring the
company meets all audit and SEC compliance
regulations.
|
|
|
·
|
Holding
directorships on the Board of subsidiary companies and Joint venture
companies.
|
|
|
·
|
Consulting
services pertaining to gasification technology, fermentation processes and
combined duel gas processes
|
|
|
·
|
Evaluation
of feedstock and its calorific values/application in
gasification processes
|
|
|
·
|
Supplying
technical due diligence materials to various institutions and investment
banks with regards to gasification and combustion steam
systems.
|
|
|
·
|
Overseeing the
manufacturing of gasification equipment with key suppliers located in
South Africa.
|
|
|
·
|
Strategy:
Constructively challenge and contribute to the development of
strategy.
|
|
|
·
|
Performance:
Scrutinise the performance of management in meeting agreed goals and
objectives and monitor the reporting of performance.
|
|
|
·
|
Risk:
Satisfy that financial information is accurate and that
financial controls and systems of risk management are robust and
defensible.
|
|
|
·
|
People:
Determination of the appropriate evels of remuneration of
executive directors and have a prime role in appointing, and where
necessary removing, senior management and in succession
planning
|
|
|
·
|
Providing
entrepreneurial leadership of the Company within a framework of prudent
and effective controls which enable risk to be assessed and
managed.
|
|
|
·
|
Setting
the Company’s strategic aims, ensures that the necessary financial and
human resources are in place for the Company to meet its objectives, and
reviews management performance.
|
|
|
·
|
Setting the
Company’s values and standards and ensures that its obligations to its
shareholders and others are understood and
met.
|
|
|
·
|
Serving
on one or more of the Board committees including Audit, Nomination and
Remuneration Committees and set out the terms of reference for each of
those committees.
|
|
Mark
LM Quinn:
|
17,948,984
shares of common stock (1)
|
|
Jessica
Hatfield:
|
13,948,984
shares of common stock (2)
|
|
Dr
Arvind Pandalai:
|
5,000,000
shares of common stock
|
|
Robert
Kohn:
|
3,000,000
shares of common stock
|
|
David
Sonnenberg
|
500,000
shares of common stock (3)
|
|
Mike
Starkie:
|
500,000
shares of common stock (4)
|
|
(1)
|
On
December 12
th
2009, Mr Quinn returned 2,100,000 shares of common stock to the
Treasury of the Company. On November 11
th
2009 Mr Quinn received 760 shares of common stock under the terms of the
Share exchange Agreement signed November 5
th
2009.
|
|
(2)
|
On
December 12
th
2009, Ms Hatfield received an additional 1,900,000 shares of common stock.
Ms Hatfield received 760 shares of common stock under the terms of he
share exchange Agreement signed November 5
th
2009.
|
|
(3)
|
On
October 29
th
,
2009, Mr Sonnenberg received an additional 250,000 shares of
common stock
|
|
(4)
|
On
October 29
th
,
2009, Mike Starkie received an additional 1, 500,000 shares of common
stock.
|
|
Dr
Arvind Pandalai
|
$ | 16,666 | ||
|
Mark
Quinn
|
$ | 5,366 | ||
|
Robert
Kohn
|
$ | 5,602 | ||
|
Jessica
Hatfield
|
$ | 5,366 | ||
|
David
Sonnenberg
|
$ | 1,532 | ||
|
Mike
Starkie
|
$ | 5,366 |
|
Item 12.
|
Security
Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters.
|
|
•
|
each
person known by us to beneficially own 5% or more of the outstanding
shares of such class of stock, based on filings with the Securities and
Exchange Commission and certain other
information,
|
|
•
|
each
of our current “named executive officers” and directors,
and
|
|
•
|
all
of our current executive officers and directors as a
group.
|
|
Amount and Nature of
|
Percentage
|
|||||||
|
Name and Address of Stockholder
|
Beneficial Ownership
|
of Class
|
||||||
|
Mark
Quinn
|
||||||||
|
15
Dippers Close
|
||||||||
|
Kemsing,
Sevenoaks, Kent TN15 6QD
|
||||||||
|
United
Kingdom
|
18,782,266 | (1) | 20.5 | % | ||||
|
Jessica
Hatfield
|
||||||||
|
45
Gunton Road Upper Clapton
|
||||||||
|
London
ES 9JT
|
||||||||
|
United
Kingdom
|
18,732,331 | (1) | 20.5 | % | ||||
|
Dr.
Arvind Pandalai
|
||||||||
|
250
Defencse Colony Hal State 11
|
||||||||
|
First
Main Bangalore 560039
|
||||||||
|
Karnataka,
India
|
5,000,000 | 5.46 | ||||||
|
Robert
Kohn
|
||||||||
|
6165
NW 123 Lane
|
||||||||
|
Coral
Springs, Florida 33076
|
3,000,000 | 3.28 | ||||||
|
David
Sonnenberg
|
||||||||
|
PO
Box 954
|
||||||||
|
Honeydew
2040 Johannesburg
|
||||||||
|
South
Africa
|
750,000 | 0.82 | ||||||
|
Mike
Starkie
|
||||||||
|
Dodhurst
Farm Cottages
|
||||||||
|
Highwoods
Lane
|
||||||||
|
Tunbridge
Wells
|
||||||||
|
Kent
TN3 9AB
|
||||||||
|
United
Kingdom
|
2,000,000 | 2.18 | ||||||
|
All
directors and executive
officers
|
||||||||
|
as
a
group
(6 persons)
|
48,264,597 | 52.7 | % | |||||
|
V.
Ravikanth
|
||||||||
|
TC
5/1025 Hridya, Chavadimukku
|
||||||||
|
Sreekariyam,
Trivandrum
|
||||||||
|
India
|
4,600,000 | 5.05 | ||||||
|
(1)
|
Includes
5,865,175 shares of our common stock owned of record by Rootchange
Limited, a company in which Mark Quinn and Jessica Hatfield each hold a
50% equity interest. Mr. Quinn and Ms. Hatfield each have
voting and dispositive powers over the shares of our common stock owned by
Rootchange Limited.
|
|
Item 13.
|
Certain
Relationships and Related
Transactions.
|
|
•
|
Our
former principal executive office and telephone number were provided by
our former President, Chief Executive Officer, Chief Financial Officer and
director, Mr. Seyfert, on a rent free
basis;
|
|
•
|
Mark
Quinn and Jessica Hatfield were shareholders of Limited at the time we
acquired Limited in November 2009 and each acquired 760 shares in
connection with such acquisition
|
|
|
·
|
Mark
Quinn and Jessica Hatfield were 50% equal shareholders of Rootchange
Limited that was acquired by Limited on April 1
st
2009 in exchange for 5,865,775 shares in
total.
|
|
|
·
|
The
Company has entered into consulting agreements with certain individual as
listed below to perform in the position of executive officers and
directors of the company. In exchange for their services, their monthly
compensation is as follows :
|
|
Dr
Arvind Pandalai (Non Executive Chairman)
|
$ | 16,666 | ||
|
Mark
Quinn (Chief Executive Officer)
|
$ | 5,366 | ||
|
Robert
Kohn (Non Executive Vice Chariman)
|
$ | 5,602 | ||
|
Jessica
Hatfield (Executive Vice President)
|
$ | 5,366 | ||
|
David
Sonnenberg (Non Executive Director)
|
$ | 1,532 | ||
|
Mike
Starkie (President and acting Chief Financial Officer)
|
$ | 5,366 |
|
|
·
|
|
Item 14.
|
Principal
Accounting Fees and Services.
|
|
Fiscal Year Ended October 31,
|
||||||||
|
Category
|
2009
|
2008
|
||||||
|
Audit
fees (1)
|
$ | 35,000 | $ | 6,500 | ||||
|
Audit-related
fees (2)
|
0 | 0 | ||||||
|
Tax
fees (3)
|
0 | 0 | ||||||
|
All
Other Fees (4)
|
50,000 | 0 | ||||||
|
(1)
|
Consists
of fees billed for the audit of our annual financial statements, review of
financial statements included in our Quarterly Reports on Form 10-QSB and
services that are normally provided by the accountant in connection with
statutory and regulatory filings or
engagements.
|
|
(2)
|
Consists
of assurance and related services that are reasonably related to the
performance of the audit and reviews of our financial statements and are
not included in “audit fees” in this
table.
|
|
(3)
|
Consists
of professional services rendered for tax compliance, tax advice and tax
planning. The nature of these tax services is tax
preparation.
|
|
(4)
|
Fees
incurred in connection with reverse acquisition
audits.
|
|
Item 15.
|
Exhibits,
Financial Statement Schedules.
|
|
Exhibit
|
||
|
Number
|
Exhibit
Description
|
|
|
3.1
|
Composite
of Articles of Incorporation.
|
|
|
3.2
|
Bylaws,
as amended to date. [Incorporated by reference to exhibit 3.2
to the Registration Statement on Form SB-2 of American Bonanza Resources
Corp. (p/k/a Clenergen Corporation), filed with the SEC on December 13,
2005.]
|
|
|
10.1
|
Share
Exchange Agreement, dated as of August 30, 2009, between Clenergen
Corporation and Clenergen Corporation Limited
(UK). [Incorporated by reference to Exhibit 2.1 to the Current
Report on Form 8-K (Date of Report: August 30, 2009) of Clenergen
Corporation, filed with the SEC on September 4, 2009.]
|
|
|
10.2
|
Commercial
Lease Agreement, dated September 11, 2009, between Archana Spinners
Limited and Clenergen India Private Limited. [Incorporated by
reference to Exhibit 10.2 to the Current Report on Form 8-K (Date of
Report: November 5, 2009) of Clenergen Corporation, filed with the SEC on
November 10, 2009.]
|
|
|
10.3
|
Agreement,
dated October 2009, between Clenergen Corporation and Star Biotechnology
Limited. [Incorporated by reference to Exhibit 10.12 to the
Current Report on Form 8-K (Date of Report: November 5, 2009) of Clenergen
Corporation, filed with the SEC on November 10, 2009.]
|
|
|
10.4
|
Research
and Development Agreement, dated October 2009, among Clenergen
Corporation, Star Biotechnology Limited and Arbour Technologies Pty
Ltd. [Incorporated by reference to Exhibit 10.13 to the Current
Report on Form 8-K (Date of Report: November 5, 2009) of Clenergen
Corporation, filed with the SEC on November 10, 2009.]
|
|
|
10.5
|
Power
Purchase Agreement dated March 31, 2009 between Clenergen India Private
Limited and PTC India Limited (formerly known as Power Trading Corporation
of India Limited). [Incorporated by reference to Exhibit 10.4
to the Current Report on Form 8-K (Date of Report: November 5, 2009) of
Clenergen Corporation, filed with the SEC on November 10,
2009.]
|
|
|
10.6
|
Memorandum
of Agreement, dated October 6, 2009, between Clenergen Corporation and
Enhanced Biofuels and Technologies India Private
Limited. [Incorporated by reference to Exhibit 10.14 to the
Current Report on Form 8-K (Date of Report: November 5, 2009) of Clenergen
Corporation, filed with the SEC on November 10, 2009.]
|
|
|
10.7
|
Memorandum
of Agreement, dated August 2009, between Clenergen India Private Limited
and Growmore Biotech Limited. [Incorporated by reference to
Exhibit 10.5 to the Current Report on Form 8-K (Date of Report: November
5, 2009) of Clenergen Corporation, filed with the SEC on November 10,
2009.]
|
|
|
10.8
|
Biomass
Supply Agreement, dated June 2009, between Clenergen Corporation Limited
and Villsam Company Limited. [Incorporated by reference to
Exhibit 10.7 to the Current Report on Form 8-K (Date of Report: November
5, 2009) of Clenergen Corporation, filed with the SEC on November 10,
2009.]
|
|
10.9
|
Strategic
Marketing Agreement, dated June 2009, between Clenergen Corporation
Limited and Villasam Company Limited. [Incorporated by
reference to Exhibit 10.8 to the Current Report on Form 8-K (Date of
Report: November 5, 2009) of Clenergen Corporation, filed with the SEC on
November 10, 2009.]
|
|
|
10.10
|
Leasehold
and Option Agreement dated September 12, 2009 between Clenergen
Corporation and Georgia Caribbean International,
Limited. [Incorporated by reference to Exhibit 10.9 to the
Current Report on Form 8-K (Date of Report: November 5, 2009) of Clenergen
Corporation, filed with the SEC on November 10, 2009.]
|
|
|
10.11
|
Memorandum
of Agreement, dated August 31, 2009, between Clenergen India Private
Limited and See Emberumanar Jeer Mutt. [Incorporated by
reference to Exhibit 10.16 to the Current Report on Form 8-K (Date of
Report: November 5, 2009) of Clenergen Corporation, filed with the SEC on
November 10, 2009.]
|
|
|
10.12
|
Biomass
Supply Agreement, dated April 1, 2009, between Clenergen India Private
Limited and IJM Constructions. [Incorporated by reference to
Exhibit 10.9 to the Current Report on Form 8-K (Date of Report: November
5, 2009) of Clenergen Corporation, filed with the SEC on November 10,
2009.]
|
|
|
10.13
|
Letter
of Maurai Kamaraj University, dated September 17, 2009 and addressed to
Clenergen Corporation Limited (UK). [Incorporated by reference
to Exhibit 10.17 to the Current Report on Form 8-K (Date of Report:
November 5, 2009) of Clenergen Corporation, filed with the SEC on November
10, 2009.]
|
|
|
10.14
|
Memorandum
of Agreement, dated December 2009, between Clenergen Corporation and
National Power Corporation.
|
|
|
10.15
|
Asset
Purchase Agreement, between Clenergen Corporation Limited and Rootchange
Limited, dated April 1, 2009.
|
|
|
10.16
|
Consulting
Agreement between Mark LM Quinn and Clenergen Corporation dated August
29th, 2009.
|
|
|
10.17
|
Consulting
Agreement between Jesscia Hatfield and Clenergen Corporation dated August
29th, 2009.
|
|
|
10.18
|
Consulting
Agreement between Dr Arvind Pandalai and Clenergen Corporation
dated August 8th, 2009.
|
|
|
10.19
|
Consulting
Agreement between Robert Kohn and Clenergen Corporation dated August 29th,
2009
|
|
|
10.20
|
Consulting
Agreement between Mike Starkie and Clenergen Corporation dated
January 1st 2010.
|
|
|
10.21
|
Consulting
Agreement between David Sonnenberg and Clenergen corporation
dated August 29th, 2009.
|
|
|
21.1
|
Subsidiaries.
|
|
|
31.1
|
Rule
13a-14(a)/15d-14(a) Certification of Principal Executive
Officer.
|
|
|
31.2
|
Rule
13a-14(a)/15d-14(a) Certification of Principal Financial
Officer.
|
|
|
32.1
|
Section
1350 Certification of Principal Executive Officer.
|
|
|
32.2
|
Section
1350 Certification of Principal Financial
Officer.
|
|
HOLTZ
RUBENSTEIN REMINICK
LLP
|
|
|
10/31/2009
|
10/31/2008
|
|||||||
|
CURRENT
ASSETS
|
||||||||
|
Cash
|
$ | 1,472 | $ | 13 | ||||
|
Prepaid
Expenses and Other
|
15,039 | - | ||||||
|
Total
Current Assets
|
16,511 | 13 | ||||||
|
FIXED
ASSETS
|
||||||||
|
Property
& Equipment, Net
|
12,901 | - | ||||||
|
Total
Fixed Assets
|
12,901 | - | ||||||
|
OTHER ASSETS
|
||||||||
|
Deposits
|
33,487 | - | ||||||
|
Total
Other Assets
|
33,487 | - | ||||||
|
TOTAL
ASSETS
|
$ | 62,899 | $ | 13 | ||||
|
10/31/2009
|
10/31/2008
|
|||||||
|
CURRENT LIABILITIES
|
||||||||
|
Accounts
Payable and Accrued Expenses
|
$ | 214,211 | $ | - | ||||
|
Payroll
Liabilities
|
6,745 | - | ||||||
|
Due
to Affiliates and Shareholders
|
330,302 | 3,460,014 | ||||||
|
Total
Current Liabilities
|
551,258 | 3,460,013 | ||||||
|
TOTAL
LIABILITIES
|
551,258 | 3,460,013 | ||||||
|
STOCKHOLDERS'
EQUITY/(DEFICIENCY)
|
||||||||
|
Preferred stock,
$0.001 par value,
Authorized:
10,000,000
Issued:
None
|
- | - | ||||||
|
Common Stock, $0.001
par value; 150,000,000 shares authorized
as of October 31, 2009;
$1.90 par value; 7,500 shares authorized as October 31, 2008; 86,941,013
and 7,500 shares issued and outstanding, respectively
|
86,941 | 14,242 | ||||||
|
Additional
paid in capital
|
3,998,562 | - | ||||||
|
Accumulated
Other Comprehensive Income/(Loss)
|
389,956 | 416,880 | ||||||
|
Accumulated
deficit during development stage
|
(4,963,818 | ) | (3,891,123 | ) | ||||
|
Total
Stockholders' Deficiency
|
(488,359 | ) | (3,460,000 | ) | ||||
|
TOTAL
LIABILITIES AND DEFICIENCY
|
$ | 62,899 | $ | 13 | ||||
|
TWELVE
|
TWELVE
|
FROM
|
||||||||||
|
MONTHS
|
MONTHS
|
INCEPTION
|
||||||||||
|
10/31/2009
|
10/31/2008
|
TO
10/31/09
|
||||||||||
|
REVENUE
|
$ | - | $ | - | $ | - | ||||||
|
COST OF SERVICES
|
- | - | - | |||||||||
|
GROSS PROFIT OR (LOSS)
|
- | - | - | |||||||||
|
GENERAL AND ADMINISTRATIVE
EXPENSES
|
1,072,695 | 797 | 2,688,775 | |||||||||
|
RESEARCH & DEVELOPMENT
|
- | 175 | 2,275,043 | |||||||||
|
OPERATING INCOME/(LOSS)
|
(1,072,695 | ) | (972 | ) | (4,963,818 | ) | ||||||
|
INTEREST EXPENSE
|
- | - | - | |||||||||
|
OTHER INCOME
|
- | - | - | |||||||||
|
INCOME/(LOSS) BEFORE INCOME
TAXES
|
(1,072,695 | ) | (972 | ) | (4,963,818 | ) | ||||||
|
PROVISION FOR INCOME TAXES
|
||||||||||||
|
Federal
|
- | - | - | |||||||||
|
State
|
- | - | - | |||||||||
|
NET INCOME/(LOSS)
|
$ | (1,072,695 | ) | $ | (972 | ) | $ | (4,963,818 | ) | |||
|
Earnings (loss) per share, basic and
diluted
|
$ | (0.0512 | ) | $ | (0.1296 | ) | $ | (0.9499 | ) | |||
|
Weighted average common shares
outstanding
|
20,950,539 | 7,500 | 5,225,390 | |||||||||
|
Comprehensive Loss:
|
||||||||||||
|
Net
Loss
|
$ | (1,072,695 | ) | $ | (972 | ) | $ | (4,963,818 | ) | |||
|
Foreign
Currency Translation Income/(Loss)
|
(26,924 | ) | 894,302 | 389,956 | ||||||||
|
Comprehensive Income/(Loss)
|
$ | (1,099,619 | ) | $ | 893,330 | $ | (4,573,862 | ) | ||||
|
ADDITIONAL
|
ACCUM. OTHER
|
|||||||||||||||||||||||||||
|
PREFERRED
|
COMMON
|
PAR
|
PAID IN
|
ACCUM
|
COMPREHENSIVE
|
TOTAL
|
||||||||||||||||||||||
|
STOCK
|
STOCK
|
VALUE
|
CAPITAL
|
DEFICIT
|
INCOME/(LOSS)
|
DEFICIENCY
|
||||||||||||||||||||||
|
Founder's
Stock - October 27, 2005 (inception)
|
- | 7,500 | $ | 14,242 | $ | - | $ | - | $ | - | $ | 14,242 | ||||||||||||||||
|
Foreign
Currency Translational Adjustment
|
(162,010 | ) | (162,010 | ) | ||||||||||||||||||||||||
|
Net
income (loss)
|
(3,157,695 | ) | - | (3,157,695 | ) | |||||||||||||||||||||||
|
Balance,
October 31, 2006
|
- | 7,500 | 14,242 | - | (3,157,695 | ) | (162,010 | ) | (3,305,462 | ) | ||||||||||||||||||
|
Foreign
Currency Translational Adjustment
|
(315,412 | ) | (315,412 | ) | ||||||||||||||||||||||||
|
Net
income (loss)
|
(732,456 | ) | - | (732,456 | ) | |||||||||||||||||||||||
|
Balance,
October 31, 2007
|
- | 7,500 | 14,242 | - | (3,890,151 | ) | (477,421 | ) | (4,353,330 | ) | ||||||||||||||||||
|
Foreign
Currency Translational Adjustment
|
894,302 | 894,302 | ||||||||||||||||||||||||||
|
Net
income (loss)
|
(972 | ) | (972 | ) | ||||||||||||||||||||||||
|
Balance,
October 31, 2008
|
- | 7,500 | 14,242 | - | (3,891,123 | ) | 416,880 | (3,460,000 | ) | |||||||||||||||||||
|
Reverse
acquisition on August 4, 2009:
|
||||||||||||||||||||||||||||
|
Reverse
acquisition issuance of consulting shares
|
21,616,695 | 21,617 | 3,409,344 | 3,430,961 | ||||||||||||||||||||||||
|
Share
cancellation per recapitalization
|
(7,500 | ) | (14,242 | ) | 14,242 | - | ||||||||||||||||||||||
|
Common
stock issued for debt cancellation on August 4, 2009, per share value
$0.08
|
7,776,350 | 7,776 | 632,523 | 640,299 | ||||||||||||||||||||||||
|
Common
stock issued for compensation on August 4, 2009, per share value
$0
|
57,547,968 | 57,548 | (57,548 | ) | - | |||||||||||||||||||||||
|
Foreign
Currency Translational Adjustment
|
(26,924 | ) | (26,924 | ) | ||||||||||||||||||||||||
|
Net
income (loss)
|
(1,072,695 | ) | (1,072,695 | ) | ||||||||||||||||||||||||
|
Balance,
October 31, 2009
|
- | 86,941,013 | $ | 86,941 | $ | 3,998,562 | $ | (4,963,818 | ) | $ | 389,956 | $ | (488,359 | ) | ||||||||||||||
|
TWELVE
|
TWELVE
|
FROM
|
||||||||||
|
MONTHS
|
MONTHS
|
INCEPTION
|
||||||||||
|
10/31/2009
|
10/31/2008
|
TO 10/31/2009
|
||||||||||
|
CASH
FLOWS FROM OPERATING ACTIVITIES
|
||||||||||||
|
Net
income (loss)
|
$ | (1,072,695 | ) | $ | (972 | ) | $ | (4,963,818 | ) | |||
|
Adjustments
to reconcile net income to net cash
used in operating
activities:
|
||||||||||||
|
Adjustments
for charges not requiring outlay of cash:
|
||||||||||||
|
Depreciation
and Amortization
|
1,140 | - | 1,140 | |||||||||
|
Changes
in operating assets and liabilitites:
|
||||||||||||
|
(Increase)/Decrease
Prepaid Expenses and Other Current Assets
|
(15,039 | ) | - | (15,039 | ) | |||||||
|
Deposits
|
(33,487 | ) | - | (33,487 | ) | |||||||
|
Increase/(Decrease)
in Accounts Payable and Accrued Expenses
|
214,211 | (32,160 | ) | 214,211 | ||||||||
|
Increase/(Decrease)
in Accrued Payroll Liabilities
|
6,745 | - | 6,745 | |||||||||
|
Total
adjustments to net income
|
173,570 | (32,160 | ) | 173,570 | ||||||||
|
Net
cash used in operating activities
|
(899,125 | ) | (33,132 | ) | (4,790,248 | ) | ||||||
|
CASH
FLOWS FROM INVESTING ACTIVITIES
|
||||||||||||
|
Purchase
of Furniture & Equipment
|
(14,041 | ) | - | (14,041 | ) | |||||||
|
Net
cash flows used in investing activities
|
(14,041 | ) | - | (14,041 | ) | |||||||
|
CASH
FLOWS FROM FINANCING ACTIVITIES
|
||||||||||||
|
Cash
Received/(Paid) from/(to) Affiliates/Shareholders
|
966,231 | (861,187 | ) | 4,384,980 | ||||||||
|
Cash
Received/(Paid) on notes payable
|
(24,681 | ) | - | 16,582 | ||||||||
|
Net
cash provided by (used in) financing activities
|
941,550 | (861,187 | ) | 4,401,562 | ||||||||
|
CASH
RECONCILIATION
|
||||||||||||
|
Effect
of Exchange Rate Changes on Cash
|
(26,924 | ) | 894,302 | 389,956 | ||||||||
|
Net
increase (decrease) in cash and cash equivalents
|
1,460 | (18 | ) | (12,771 | ) | |||||||
|
Cash
and cash equivalents - beginning balance
|
13 | 31 | 14,244 | |||||||||
|
CASH
AND CASH EQUIVALENTS BALANCE END OF PERIOD
|
$ | 1,473 | $ | 13 | $ | 1,473 | ||||||
|
Supplemetal
Disclosures of Cash Flow Information:
|
||||||||||||
|
Common
stock issued for debt cancellation
|
$ | 4,069,085 | $ | - | $ | 4,069,085 | ||||||
|
Common
stock issued in recapitalization
|
$ | 2,175 | $ | - | $ | 2,175 | ||||||
|
Furn
& Equip
|
$ | 12,339 | ||
|
Transportation
|
1,701 | |||
|
Accum
Deprec
|
( 1,139 | ) | ||
|
Net
Book Value
|
$ | 12,901 |
|
2010
|
$ | 93,500 | ||
|
2011
|
93,500 | |||
|
2012
|
93,500 | |||
|
2013
|
93,500 | |||
|
2014
|
93,500 | |||
|
Thereafter
|
1,258,000 | |||
| $ | 1,725,500 |
|
October
31,
|
October
31,
|
|||||||
|
|
2009
|
2008
|
||||||
|
Net
deferred tax assets - Non-current:
|
||||||||
|
|
||||||||
|
Expected
income tax benefit from NOL carry-forwards
|
$ | 1,116,839 | $ | 856,047 | ||||
|
Less
Valuation Allowance
|
(1,116,839 | ) | (856,047 | ) | ||||
|
Deferred
tax assets, net of valuation allowance
|
$ | - | $ | - | ||||
|
For the Year Ended
|
||||||||
|
December 31,
|
December 31,
|
|||||||
|
2009
|
2008
|
|||||||
|
United
States statutory rate
|
15.00 | % | 15.00 | % | ||||
|
United
Kingdom statutory rate
|
22.00 | % | 21.00 | % | ||||
|
Indian
statutory rate
|
30.09 | % | 30.09 | % | ||||
|
Increase
(reduction) in income taxes resulting from:
|
||||||||
|
Net
Operating Loss (“NOL”) carry-forwards
|
(67.09 | )% | (67.09 | )% | ||||
|
Effective
Income Tax Rate
|
0.0 | % | 0.0 | % | ||||
|
Date: March
15, 2010
|
Clenergen
Corporation
|
|
|
By:
|
/s/
Mark
Quinn
|
|
|
Mark
Quinn
|
||
|
Chief
Executive Officer
|
||
|
Capacities
|
Date
|
|||
|
/s/
Mark
Quinn
|
Chief
Executive Officer
|
March
15, 2010
|
||
|
Mark
Quinn
|
and
Director (Principal Executive
|
|||
|
Officer)
|
||||
|
/s/
Mike
Starkie
|
President
and Acting Chief
|
March
15, 2010
|
||
|
Mike
Starkie
|
Financial
Officer (Principal
|
|||
|
Financial
and Accounting Officer)
|
||||
|
/s/ Dr.
Arvind
Pandalai
|
Director
|
March
15, 2010
|
||
|
Dr.
Arvind Pandalai
|
||||
|
/s/
Robert
Kohn
|
Director
|
March
15, 2010
|
||
|
Robert
Kohn
|
||||
|
/s/
David
Sonnenberg
|
Director
|
March
15, 2010
|
||
|
David
Sonnenberg
|
||||
|
/s/
Jessica
Hatfield
|
Executive
Vice President and Director
|
March
15, 2010
|
||
|
Jessica
Hatfield
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|